PriceTargets.com logo

UroGen Pharma - URGN Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $19.00
  • Forecasted Upside: 131.14 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$8.22 As of 10/3/2022 01:46 PM ET
▼ -0.1 (-1.20%)

This chart shows the closing price for URGN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New UroGen Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for URGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for URGN

Analyst Price Target is $19.00
▲ +131.14% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for UroGen Pharma in the last 3 months. The average price target is $19.00, with a high forecast of $26.00 and a low forecast of $11.00. The average price target represents a 131.14% upside from the last price of $8.22.

This chart shows the closing price for URGN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in UroGen Pharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/11/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/10/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/8/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/6/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/6/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/5/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/3/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/3/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/27/2022Berenberg BankInitiated CoverageBuy$20.00High
3/22/2022The Goldman Sachs GroupBoost TargetNeutral$10.00 ➝ $11.00High
3/22/2022HC WainwrightLower Target$34.00 ➝ $26.00High
1/18/2022HC WainwrightLower TargetBuy$50.00 ➝ $34.00High
4/27/2021HC WainwrightLower TargetBuy$57.00 ➝ $50.00Low
3/16/2021HC WainwrightReiterated RatingBuyLow
1/14/2021HC WainwrightReiterated RatingBuyHigh
11/10/2020OppenheimerLower Target$48.00 ➝ $40.00Low
9/21/2020JPMorgan Chase & Co.Lower Target$31.00 ➝ $26.00Medium
9/8/2020HC WainwrightReiterated RatingBuyMedium
8/10/2020Stifel NicolausReiterated RatingBuy$46.00High
5/8/2020HC WainwrightReiterated RatingBuyLow
5/7/2020Stifel NicolausReiterated RatingBuy$46.00Low
5/7/2020OppenheimerInitiated CoverageBuy$47.00Low
4/17/2020OppenheimerBoost TargetOutperform$45.00 ➝ $47.00High
4/16/2020HC WainwrightBoost Target$53.00 ➝ $57.00High
4/15/2020Stifel NicolausReiterated RatingBuyHigh
4/13/2020HC WainwrightReiterated RatingBuy$75.00 ➝ $53.00High
4/6/2020OppenheimerLower TargetOutperform$47.00 ➝ $45.00High
3/4/2020HC WainwrightReiterated RatingBuy$75.00High
3/2/2020Stifel NicolausReiterated RatingBuy$40.00High
1/16/2020CowenReiterated RatingBuyHigh
1/13/2020OppenheimerLower TargetOutperform$62.00 ➝ $52.00High
1/9/2020National SecuritiesInitiated CoverageNeutral$37.00Medium
12/19/2019HC WainwrightReiterated RatingBuy$75.00High
11/27/2019HC WainwrightReiterated RatingBuy$75.00Low
11/13/2019OppenheimerLower Target$70.00 ➝ $62.00Low
11/13/2019JPMorgan Chase & Co.Lower TargetNeutral$40.00 ➝ $39.00Medium
11/11/2019CowenReiterated RatingBuyMedium
10/21/2019HC WainwrightSet TargetBuy$75.00Low
10/20/2019Stifel NicolausSet TargetBuy$41.00Low
9/24/2019CowenReiterated RatingBuyMedium
9/24/2019Stifel NicolausReiterated RatingBuy$61.00High
5/30/2019JPMorgan Chase & Co.Initiated CoverageNeutral$41.00Medium
5/29/2019The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$50.00 ➝ $50.00High
5/28/2019HC WainwrightSet TargetBuy$75.00High
5/6/2019CowenReiterated RatingBuyMedium
3/19/2019OppenheimerReiterated RatingBuyLow
3/5/2019Stifel NicolausReiterated RatingBuy$63.00High
3/1/2019Raymond JamesSet TargetBuy$57.00Low
3/1/2019HC WainwrightReiterated RatingBuy$75.00Medium
2/28/2019OppenheimerSet TargetBuy$70.00Medium
1/29/2019HC WainwrightInitiated CoverageBuy$82.00Low
11/13/2018OppenheimerSet TargetBuy$75.00High
11/8/2018Jefferies Financial GroupInitiated CoverageBuy$77.00High
9/13/2018Stifel NicolausInitiated CoverageBuy$70.00Medium
8/14/2018OppenheimerSet TargetBuy$75.00High
8/14/2018CowenReiterated RatingBuyHigh
5/22/2018OppenheimerSet TargetBuy$75.00Medium
5/15/2018OppenheimerSet TargetBuy$75.00High
5/15/2018CowenReiterated RatingBuyHigh
4/4/2018UBS GroupUpgradeMarket Perform ➝ OutperformHigh
4/4/2018Raymond JamesUpgradeMarket Perform ➝ OutperformHigh
4/3/2018OppenheimerReiterated RatingBuy$62.00 ➝ $75.00High
3/22/2018OppenheimerReiterated RatingBuyLow
3/19/2018Jefferies Financial GroupReiterated RatingBuyLow
3/16/2018LADENBURG THALM/SH SHReiterated RatingBuy ➝ Buy$65.00High
3/15/2018OppenheimerSet TargetBuy$62.00High
1/2/2018LADENBURG THALM/SH SHInitiated CoverageBuy ➝ Buy$50.00High
11/15/2017CowenReiterated RatingBuyN/A
11/15/2017CIBCReiterated RatingOutperform ➝ Outperform$32.00 ➝ $51.00N/A
11/15/2017Raymond JamesDowngradeOutperform ➝ Market PerformN/A
11/15/2017UBS GroupDowngradeOutperform ➝ Market PerformN/A
11/14/2017OppenheimerSet TargetOutperform$32.00 ➝ $51.00N/A
10/9/2017Jefferies Financial GroupBoost TargetBuy$27.00 ➝ $37.00N/A
(Data available from 10/3/2017 forward)

News Sentiment Rating

1.07 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/7/2022
  • 2 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/6/2022
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/6/2022
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
6/5/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/5/2022
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/4/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
9/3/2022
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/3/2022

Current Sentiment

  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

UroGen Pharma logo
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Read More

Today's Range

Now: $8.22
Low: $8.13
High: $8.52

50 Day Range

MA: $8.13
Low: $7.21
High: $9.41

52 Week Range

Now: $8.22
Low: $4.85
High: $19.66

Volume

211 shs

Average Volume

129,517 shs

Market Capitalization

$186.93 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.77

Frequently Asked Questions

What sell-side analysts currently cover shares of UroGen Pharma?

The following Wall Street sell-side analysts have issued research reports on UroGen Pharma in the last year: Berenberg Bank, HC Wainwright, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for URGN.

What is the current price target for UroGen Pharma?

3 Wall Street analysts have set twelve-month price targets for UroGen Pharma in the last year. Their average twelve-month price target is $19.00, suggesting a possible upside of 131.1%. HC Wainwright has the highest price target set, predicting URGN will reach $26.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $11.00 for UroGen Pharma in the next year.
View the latest price targets for URGN.

What is the current consensus analyst rating for UroGen Pharma?

UroGen Pharma currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe URGN will outperform the market and that investors should add to their positions of UroGen Pharma.
View the latest ratings for URGN.

What other companies compete with UroGen Pharma?

Other companies that are similar to UroGen Pharma include InterCure, Akouos, Clene, Satsuma Pharmaceuticals and Kamada. Learn More about companies similar to UroGen Pharma.

How do I contact UroGen Pharma's investor relations team?

UroGen Pharma's physical mailing address is 400 Alexander Park, Princeton NJ, 08540. The company's listed phone number is (646) 768-9780 and its investor relations email address is [email protected] The official website for UroGen Pharma is www.urogen.com. Learn More about contacing UroGen Pharma investor relations.